CYP2C9 and hypertensive disorder: However, in terms of CYP2C9 polymorphism, ∗1/∗3 genotype did not affect the hypertension control rate in valsartan treatment (∗1/∗3 vs. ∗1/∗1: OR 0.607, 95% CI 0.263–1.402, P = 0.242).